Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of IA regimen in induction chemotherapy of de-novo AML based on peripheral residual disease
ChiCTR-OIC-16007764Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of idarubicin, cytarabine and homoharringtonine in acute myeloid leukemia (AML) (3 arms), sponsored by Ruijin Hospital. Primary endpoints: Complete Remission Rate, Relapse Free Survival and 1 more. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
idarubicincytarabinehomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OIC-16007764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16007764.